Skip to main content
. Author manuscript; available in PMC: 2021 Nov 19.
Published in final edited form as: Neuroimage. 2021 Aug 24;243:118514. doi: 10.1016/j.neuroimage.2021.118514

Fig. 5.

Fig. 5.

Comparison of the ability of DeepAtrophy PAIIR measure, ALOHA atrophy rate, and PACC score change rate to detect differences in the rates of disease progression between normal controls (A− NC) and three disease groups: preclinical AD (A+ NC), early prodromal AD (A+ eMCI) and late prodromal AD (A+ lMCI) using follow-up timepoints between (a) 180 to 400 days from baseline (one-year clinical trial scenario) and (b) 400 to 800 days from baseline (two-year clinical trial scenario). In each subplot, the Wilcoxon signed-rank test was conducted to compare each patient group with the control group, and the p-values were shown for each comparison. Abbreviations: PAIIR = predicted-to-actual interscan interval ratio; ALOHA = Automatic Longitudinal Hippocampal Atrophy software/package; PACC = Preclinical Alzheimer’s Cognitive Composite; A+/A− = beta-amyloid positive/negative; NC = cognitively normal adults; eMCI = early mild cognitive impairment; lMCI = late mild cognitive impairment; N = number of subjects in the diagnosis group.